tetrabenazine has been researched along with Parkinsonian Disorders in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (28.57) | 29.6817 |
2010's | 11 (52.38) | 24.3611 |
2020's | 4 (19.05) | 2.80 |
Authors | Studies |
---|---|
Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A | 1 |
Shah, C | 1 |
Checkoway, H; Criswell, SR; Lenox-Krug, J; Moerlein, SM; Nielsen, SS; Perlmutter, JS; Racette, BA; Sheppard, L; Warden, MN | 1 |
Espay, AJ; Gupta, HV; Sharma, VD | 1 |
Alexander, PK; Bozinvski, S; Jones, G; Lie, Y; Mulligan, RS; Rowe, CC; Sivaratnam, C; Villemagne, VL; Young, K | 1 |
Estevez-Fraga, C; López-Sendón Moreno, JL; Zeun, P | 1 |
Cervantes-Arriaga, A; Díaz-Meneses, IE; Kerik, NE; Pérez-Lohman, C; Rodríguez-Violante, M | 1 |
Baqi, Y; Barber, J; Correa, M; Lee, CA; Lendent, C; López-Cruz, L; Milligan, M; Müller, CE; Nunes, EJ; Pardo, M; Podurgiel, SJ; Salamone, JD; Thompson, A; Valverde, O; Yohn, SE | 1 |
Chan, P; Kung, HF; Liu, Y; Pan, X; Tang, R; Tao, G; Yue, F; Zhu, L | 1 |
Agarwal, PA; Appel-Cresswell, S; Dinelle, K; Farrer, MJ; Felicio, AC; Heffernan, N; McKenzie, J; Road, JD; Schulzer, M; Sossi, V; Stoessl, AJ; Wszolek, ZK | 1 |
Aoki, N; Baker, M; Boeve, BF; Dickson, DW; Fujioka, S; Parisi, JE; Rademakers, R; Ross, OA; Sanchez-Contreras, M; Sossi, V; Stoessl, AJ; Strongosky, AJ; Tacik, P; Wszolek, ZK | 1 |
Appel-Cresswell, S; Dickson, DW; Dinelle, K; Farrer, MJ; McCormick, SE; McKenzie, J; Rajput, A; Rajput, AH; Robinson, CA; Silva, V; Sossi, V; Stoessl, AJ; Thompson, C; Vilariño-Güell, C | 1 |
Correa, M; Dortche, K; Podurgiel, SJ; Salamone, JD; Yohn, SE | 1 |
Hasegawa, K; Kowa, H; Stoessl, AJ; Wszolek, ZK; Yagishita, S; Yokoyama, T | 1 |
Alexander, M; Burton, NC; Griswold, M; Guilarte, TR; McGlothan, JL; Pham, L; Schneider, JS; Syversen, T; Verina, T; Wong, DF; Zhou, Y | 1 |
Arbizu, J; Blesa, J; Cavada, C; Collantes, M; García-García, D; Iglesias, E; Juri, C; Martí-Climent, J; Obeso, JA; Peñuelas, I; Prieto, E; Richter, JA; Rodríguez-Oroz, MC; Zubieta, JL | 1 |
Kang, GA; Lee, AJ; Poon, LH | 1 |
Andersson, DR; Bergquist, F; Nissbrandt, H | 1 |
Hunter, C; Jankovic, J; Kenney, C | 1 |
Camborde, ML; Doudet, DJ; Greene, J; Holden, JE; Kornelsen, RA; McCormick, SE; Ruth, TJ; Sossi, V; Studenov, AR; Topping, GJ | 1 |
Adams, RJ; Alexander, M; Brasić, JR; Burton, NC; Chen, MK; Guilarte, TR; Kumar, A; Kuwabara, H; McGlothan, JL; Verina, T; Wong, DF; Zhou, Y | 1 |
2 review(s) available for tetrabenazine and Parkinsonian Disorders
Article | Year |
---|---|
Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.
Topics: Aged; Dementia; Dyskinesia, Drug-Induced; Humans; Parkinsonian Disorders; Risk Factors; Tardive Dyskinesia; Tetrabenazine; Valine | 2018 |
Role of tetrabenazine for Huntington's disease-associated chorea.
Topics: Animals; Clinical Trials as Topic; Humans; Huntington Disease; Parkinsonian Disorders; Sleep Stages; Tetrabenazine | 2010 |
19 other study(ies) available for tetrabenazine and Parkinsonian Disorders
Article | Year |
---|---|
The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Buspirone; Catalepsy; Depression; Huntington Disease; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Tetrabenazine | 2022 |
Comment on Akbar et al., "Valbenazine-induced parkinsonism".
Topics: Antipsychotic Agents; Humans; Parkinsonian Disorders; Tardive Dyskinesia; Tetrabenazine; Valine | 2020 |
[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Humans; Male; Manganese; Middle Aged; Occupational Diseases; Occupational Exposure; Parkinsonian Disorders; Positron-Emission Tomography; Tetrabenazine; Young Adult | 2020 |
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine | 2020 |
Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Brain Chemistry; Case Management; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Molecular Imaging; Neuroimaging; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Tetrabenazine; Vesicular Monoamine Transport Proteins; Young Adult | 2017 |
Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center.
Topics: Adult; Aged; Brain; Carbon Radioisotopes; Female; Humans; Male; Mexico; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tetrabenazine; Tomography, Emission-Computed, Single-Photon | 2018 |
The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
Topics: Adrenergic Uptake Inhibitors; Animals; Catalepsy; Data Interpretation, Statistical; Disease Models, Animal; Dose-Response Relationship, Drug; Jaw; Male; Mice; Mice, Knockout; Motor Activity; Movement; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Tetrabenazine; Tremor; Vesicular Monoamine Transport Proteins; Xanthines | 2013 |
Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133).
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fluorine Radioisotopes; Linear Models; Macaca fascicularis; Male; Parkinsonian Disorders; Positron-Emission Tomography; Severity of Illness Index; Tetrabenazine; Time Factors; Vesicular Monoamine Transport Proteins | 2014 |
In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.
Topics: Adult; Aniline Compounds; Corpus Striatum; Depression; Dopamine; Dynactin Complex; Fluorine Radioisotopes; Humans; Hypoventilation; Microtubule-Associated Proteins; Middle Aged; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Raclopride; Serotonin; Sulfides; Tetrabenazine; Tomography, Emission-Computed | 2014 |
A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.
Topics: Aged; Aged, 80 and over; C9orf72 Protein; Dementia; Family Health; Female; Humans; Intercellular Signaling Peptides and Proteins; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Longitudinal Studies; Male; Middle Aged; Motor Neuron Disease; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Progranulins; Protein Serine-Threonine Kinases; Proteins; Psychiatric Status Rating Scales; Severity of Illness Index; tau Proteins; Technetium Tc 99m Exametazime; Tetrabenazine; Tomography, Emission-Computed, Single-Photon | 2014 |
Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.
Topics: Aged; Aged, 80 and over; Brain; Carbon Isotopes; Dopamine Agents; Family Health; Fluorodeoxyglucose F18; Humans; Levodopa; Middle Aged; Molecular Chaperones; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Tetrabenazine | 2014 |
The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Jaw; Male; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Random Allocation; Rats, Sprague-Dawley; Selegiline; Tetrabenazine; Tremor; Vesicular Monoamine Transport Proteins | 2016 |
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Isoleucine; Japan; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Tetrabenazine; Tyrosine | 2009 |
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism.
Topics: Amphetamine; Animals; Cocaine; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Image Processing, Computer-Assisted; Macaca fascicularis; Male; Manganese; Parkinsonian Disorders; Positron-Emission Tomography; Substantia Nigra; Synaptic Transmission; Tetrabenazine; Tyrosine 3-Monooxygenase | 2008 |
Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Topics: Animals; Brain Mapping; Carbon Radioisotopes; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Female; Macaca fascicularis; Male; Parkinsonian Disorders; Positron-Emission Tomography; Putamen; Severity of Illness Index; Signal Processing, Computer-Assisted; Tetrabenazine | 2010 |
Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Topics: Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Dendrites; Disease Models, Animal; Dopamine; Extracellular Fluid; Female; Motor Activity; Movement; Movement Disorders; Neural Pathways; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Substantia Nigra; Synaptic Transmission; Tetrabenazine; Vesicular Monoamine Transport Proteins | 2006 |
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
Topics: Adult; Age of Onset; Anti-Dyskinesia Agents; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Hyperkinesis; Male; Middle Aged; Myoclonus; Parkinsonian Disorders; Prevalence; Retrospective Studies; Severity of Illness Index; Tetrabenazine; Tics; Time | 2007 |
In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.
Topics: Adrenergic Agents; Animals; Brain; Carbon Radioisotopes; Image Processing, Computer-Assisted; Male; Oxidopamine; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Tetrabenazine; Vesicular Monoamine Transport Proteins | 2007 |
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.
Topics: Animals; Autoradiography; Brain; Carbon Isotopes; Carrier Proteins; Cocaine; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Glial Fibrillary Acidic Protein; Isoquinolines; Male; Neurons; Papio anubis; Parkinsonian Disorders; Positron-Emission Tomography; Raclopride; Tetrabenazine; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2008 |